Top Markets
Coin of the day
Nuformix plc Nuformix plc

Nuformix plc

NFX
Rangering i aksjer #20651
Nuformix plc operates in the field of pharmaceutical development for treating... Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Aksjekurs
$0.00244926
Markedsverdi
$51.67K
Endring (1 dag)
5.88%
Endring (1 år)
110.15%
Land
GB
Handel Nuformix plc (NFX)

Kategori

Utbytteavkastning for Nuformix plc (NFX)
Nuformix plc (aksjesymbol: NFX) sin utbytteavkastning (TTM) per 2024-09-30 er: 0.00%
Gjennomsnittlig utbytteavkastning de siste 5 årene: 0.00%
Utbytteavkastning for Nuformix plc (NFX) fra 2014 til 2026
Utbytteavkastning ved slutten av hvert år (TTM)
År Utbytteavkastning Endre
2026 (TTM) 0.00% 0.00%
2025 0.00% 0.00%
2024 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
2016 0.00% 0.00%
2014 0.00% 0.00%
Utbytteavkastning (TTM) for lignende selskaper eller konkurrenter